Skip to main content

TriLink Gets SBIR Grant for DNA Ligase Studies

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – TriLink BioTechnologies today said that it has received a Phase II Small Business Innovation Research grant of around $725,000 to continue its studies of DNA ligase.

The San Diego-based firm said that it will use the funds to continue its research on chemically modified components as a means of enhancing ligation fidelity in a variety of applications including SNP detection, proximity ligation, and sequencing by ligation.

TriLink CEO Richard Hogrefe said in a statement that the firm is "confident we will soon offer a number of novel ligation products to compliment our CleanAmp PCR line of products."

TriLink said the latest award is its fourth Phase II grant and will be provided through February 2012.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.